Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 1/2023

27-10-2022 | Myocardial Infarction | Invited Editorial

Nicorandil — an Effective Multitarget Drug for Cardioprotection?

Authors: Lucie Pearce, Richard D. Carr, Derek M. Yellon, Sean M. Davidson

Published in: Cardiovascular Drugs and Therapy | Issue 1/2023

Login to get access

Excerpt

Although nicorandil has been in clinical use as a treatment for angina since the 1980s, it remains a fascinating drug with potential actions in cardiac ischaemia. Unusually, it has dual properties as both a nitric oxide (NO) donor and KATP channel opener, by which it can cause coronary artery vasodilation, as well as cardioprotection against ischaemia and reperfusion (I/R) injury. As such, it may be an attractive “multitarget” drug for cardioprotection [1]. A recently published article in Cardiovascular Drugs and Therapy presents evidence that nicorandil may suppress ischaemia-induced ventricular arrhythmias (VA) [2]. In this commentary, we discuss this article in the context of the recent CHANGE clinical trial which saw multiple benefits of nicorandil in the setting of ST-elevation myocardial infarction (STEMI) [3]. …
Literature
1.
Davidson SM, Ferdinandy P, Andreadou I, et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol. 2019;73(1):89–99.CrossRef
2.
Kobara M, Amano T, Toba H, Nakata T. Nicorandil suppresses ischemia-induced norepinephrine release and ventricular arrhythmias in hypertrophic hearts. Cardiovasc Drugs Ther. 2022.
3.
Qian G, Zhang Y, Dong W, et al. Effects of nicorandil administration on infarct size in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the CHANGE trial. J Am Heart Assoc. 2022;11(18):e026232.CrossRef
4.
Ong MEH, Perkins GD, Cariou A. Out-of-hospital cardiac arrest: prehospital management. Lancet. 2018;391(10124):980–8.CrossRef
5.
Horinaka S, Kobayashi N, Yabe A, et al. Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovasc Drugs Ther. 2004;18(1):13–22.CrossRef
6.
Campo G, Pavasini R, Morciano G, et al. Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. Data Brief. 2017;14:197–205.CrossRef
7.
Ishii H, Ichimiya S, Kanashiro M, et al. Effect of intravenous nicorandil and preexisting angina pectoris on short- and long-term outcomes in patients with a first ST-segment elevation acute myocardial infarction. Am J Cardiol. 2007;99(9):1203–7.CrossRef
8.
Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370(9597):1483–93.CrossRef
9.
Birnbaum Y, Ye R, Ye Y. Aspirin blocks the infarct-size limiting effect of ischemic postconditioning in the rat. Cardiovasc Drugs Ther. 2021.
10.
Ye R, Jneid H, Alam M et al. Do we really need aspirin loading for STEMI? Cardiovasc Drugs Ther. 2022.
11.
Tarkin JM, Kaski JC. Vasodilator therapy: nitrates and nicorandil. Cardiovasc Drugs Ther. 2016;30(4):367–78.CrossRef
12.
Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR. Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol. 2004;287(2):H841–9.CrossRef
13.
Imagawa J, Baxter GF, Yellon DM. Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol. 1998;31(1):74–9.CrossRef
14.
Rossello X, Yellon DM. The RISK pathway and beyond. Basic Res Cardiol. 2018;113(1):2.CrossRef
15.
Chen F, Chen ZQ, Zhong GL, Zhu JJ. Nicorandil inhibits TLR4/MyD88/NF-κB/NLRP3 signaling pathway to reduce pyroptosis in rats with myocardial infarction. Exp Biol Med (Maywood). 2021;246(17):1938–47.CrossRef
16.
Carr CS, Yellon DM. Ischaemic preconditioning may abolish the protection afforded by ATP-sensitive potassium channel openers in isolated human atrial muscle. Basic Res Cardiol. 1997;92(4):252–60.CrossRef
17.
IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359(9314):1269–75.
18.
Dana A, Yellon DM. ATP dependent K+ channel: a novel therapeutic target in unstable angina. Eur Heart J. 1999;20(1):2–5.
19.
Heusch G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol. 2019;114(6):45.CrossRef
20.
Bonfig NL, Soukup CR, Shah AA et al. Increasing myocardial edema is associated with greater microvascular obstruction in ST-segment elevation myocardial infarction. Am J Physiol Heart Circ Physiol. 2022;323(4):H818–24.
21.
Hongo M, Takenaka H, Uchikawa S, Nakatsuka T, Watanabe N, Sekiguchi M. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol. 1995;75(4):246–50.CrossRef
22.
Hubert A, Seitz A, Pereyra VM, Bekeredjian R, Sechtem U, Ong P. Coronary artery spasm: the interplay between endothelial dysfunction and vascular smooth muscle cell hyperreactivity. Eur Cardiol. 2020;15:e12.CrossRef
23.
Nazir SA, McCann GP, Greenwood JP, et al. Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. Eur Heart J. 2016;37(24):1910–9.CrossRef
Metadata
Title
Nicorandil — an Effective Multitarget Drug for Cardioprotection?
Authors
Lucie Pearce
Richard D. Carr
Derek M. Yellon
Sean M. Davidson
Publication date
27-10-2022
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 1/2023
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-022-07397-x

Other articles of this Issue 1/2023

Cardiovascular Drugs and Therapy 1/2023 Go to the issue

Original Article

Differential Expression of LOXL1-AS1 in Coronary Heart Disease and its Regulatory Mechanism in ox-LDL-Induced Human Coronary Artery Endothelial Cell Pyroptosis

Original Article

Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study

Review Article

Spontaneous Reperfusion in Patients with Transient ST-Elevation Myocardial Infarction—Prevalence, Importance and Approaches to Management

Correction

Correction to: Cardiovascular Event Rates in Statin‑Treated Korean Patients with Cardiovascular Disease: Estimates from a Real‑World Population Using Electronic Medical Record Data

Correction

Correction to: The Comparative Effectiveness and Safety of Different Anticoagulation Strategies for Treatment of Left Atrial Appendage Thrombus in the Setting of Chronic Anticoagulation for Atrial Fibrillation or Flutter

Original Article

Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data